Tang M, Wierup P, Terp K, Ingerslev J, Sørensen B
Department of Cardiothoracic Surgery, Aarhus University Hospital, Skejby, Denmark.
Haemophilia. 2009 Jan;15(1):101-7. doi: 10.1111/j.1365-2516.2008.01895.x.
Today the populations of haemophilia patients in many countries have a higher life expectancy than previously known, and age-related disorders such as arterial disease are expected to become more prevalent, calling for surgical intervention. Cardiac surgery constitutes a major haemostatic challenge because of sternotomy, the need of total heparinization, extracorporal circulation, mild hypothermia and cardiac arrest. To evaluate our current experience and results with cardiac surgery in patients with haemophilia the present case series report on six patients with haemophilia A (Severe = 1, Moderate = 1, Mild = 4) undergoing cardiac surgery (coronary artery bypass grafting; CABG = 2, aortic valve replacement = 1, CABG + aortic valve replacement = 2, ventricular resection + mitral valve reconstruction = 1). The present paper provides detailed information on the haemostatic treatment regimens adopted (factor concentrate dosages, timing and duration) and postoperative thromboprophylaxis (dosing and duration of low molecular weight heparin). Moreover, we present data on concomitant disorders (hypertension, hypercholesterolaemia, atrial fibrillation and diabetes), left ventricle ejection fraction (30-60%), type of anaesthesia, total amount of heparin (34 500-53 500 IU) and duration of extracorporeal circulation (80-115 min). Clinical outcomes included: re-operation because of bleeding (none), transfusion requirements, peri- and postoperative blood loss and complications and postoperative development of inhibitors (none). Clinical outcomes were compared with a control group of patients (n = 5993) without haemophilia and we found no difference in postoperative morbidity. Adopting meticulously supervised haemostatic treatment regimens, we have successfully performed major cardiac surgery in patients with haemophilia A. The clinical outcome as well as the severity and incidence of postoperative complications were similar to patients without haemophilia.
如今,许多国家血友病患者的预期寿命比以前所知的更长,诸如动脉疾病等与年龄相关的病症预计会变得更加普遍,这就需要进行外科干预。心脏手术构成了一项重大的止血挑战,原因在于胸骨切开术、全身肝素化的需求、体外循环、轻度低温以及心脏骤停。为了评估我们目前在血友病患者心脏手术方面的经验和结果,本病例系列报告了6例甲型血友病患者(重度 = 1例,中度 = 1例,轻度 = 4例)接受心脏手术的情况(冠状动脉旁路移植术;CABG = 2例,主动脉瓣置换术 = 1例,CABG + 主动脉瓣置换术 = 2例,心室切除术 + 二尖瓣重建术 = 1例)。本文提供了所采用的止血治疗方案(凝血因子浓缩剂剂量、时间和持续时间)以及术后血栓预防(低分子量肝素的剂量和持续时间)的详细信息。此外,我们还展示了关于伴随病症(高血压、高胆固醇血症、心房颤动和糖尿病)、左心室射血分数(30 - 60%)、麻醉类型、肝素总量(34500 - 53500国际单位)以及体外循环持续时间(80 - 115分钟)的数据。临床结果包括:因出血而再次手术(无)、输血需求、围手术期和术后失血及并发症以及术后抑制剂的产生(无)。将临床结果与一组无血友病的对照组患者(n = 5993)进行比较,我们发现术后发病率没有差异。通过采用精心监督的止血治疗方案,我们成功地为甲型血友病患者实施了重大心脏手术。临床结果以及术后并发症的严重程度和发生率与无血友病的患者相似。